Volunteering for Cancer Research: An Act of Love Penn Medicine News News Motivated by generations past, present, and future, two patients participating in the first-of-its-kind clinical trial are testing an experimental approach to stop cancer in its tracks at the earliest stages of development at the Basser Center. Latest News Basser Jean Bash Brings Out Celebrities for a Good Cause Bloomberg News | November 2022 Grammy Award-winning artist, songwriter, and actress Sara Bareilles performed at the Basser Center's fourth Basser Jean Bash last week in New York City. The sold-out event raised nearly $17 million to help find a cure for BRCA-related cancers. See What Your Favorite Stars Are Up To: Sara Bareilles People News | November 2022 Sara Bareilles shows off her smile while attending the 4th Annual Basser Jean Bash held at The Glasshouse in N.Y.C. on Nov. 15, 2022. Basser Center Holds Fundraiser in Manhattan to Help Cure Cancer abc7NY News | November 2022 The Basser Center held its Basser Jean Bash on November 15th in Manhattan where all attendees wore their most stylish denim. The event it was an event about your "genes" that helped to raise money to find a cure for BRCA-related cancers. Basser Center Holds Fundraiser In NYC To Help Cure Cancer MSN.com News | November 2022 The Basser Center's celebrated their 10th year anniversary with a fundraiser that helps to raise money to find a cure for BRCA-related cancers. Analysis of Matched Primary and Recurrent BRCA1/2 Mutation-Associated Tumors Identifies Recurrence-Specific Drivers Nature Communications News | November 2022 The Basser Center research team worked to address outstanding questions about cancer recurrence in BRCA1/2 mutation carriers by performing an analysis of paired primary and recurrent BRCA1/2 mutation-associated tumors. Penn Study Illuminates Why Cancers Caused by BRCA Mutations Recur Penn Medicine News News | November 2022 Our research team at the Basser Center for BRCA uncovers possible drivers of recurrent breast and ovarian cancers among women carrying high-risk genetic mutations, pointing to methods to more effectively treat disease. Research Groups Across the US Testing Vaccines to Help Prevent, Terminate Cancer ABC10 News San Diego News | October 2022 Basser executive director, Susan Domchek, MD, speaks on a vaccine that could prevent breast cancer from developing in certain patients. She says, “We’re in the midst of a trial where we’re first vaccinating BRCA1 and BRCA2 mutation carriers who have had cancer of any type. Then we will start vaccinating BRCA1 and BRCA2 mutation carriers who have never had any cancers.” For Patients with Earliest Stage of Breast Cancer, How Much Treatment is Enough? USA Today News | October 2022 Doctors are now trying to “right-size” care for patients with ductal carcinoma in situ, what’s sometimes called “stage zero” breast cancer. Susan Domchek, MD, was quoted on these treatment opportunities and risks for patients. What’s the BRCA Gene, and How Does It Affect Breast Cancer? Katie Couric Media News | October 2022 Susan Domchek, MD discusses the significance of genetics, genetic testing, the risk of developing cancer with a BRCA gene mutation and more. Groundbreaking Study to Test a Breast Cancer Vaccine Fox29 News | October 2022 Dr. Susan Domchek, executive director of the Basser Center, is interviewed with her patient, Karen, on what leading a vaccine trial to prevent breast cancer can really mean for patients and their families. After Giving Up on Cancer Vaccines, Doctors Start to Find Hope The New York Times News | October 2022 Susan Domchek, MD, Basser Center executive director, discusses emerging efforts to create cancer vaccines for diseases including those delivered after patients have blood tests to find cancer cells before they show up in scans or standard tests. The Race to Make a Vaccine for Breast Cancer TIME News | October 2022 Robert Vonderheide, MD, PhD, director of the Abramson Cancer Center, and Susan Domchek, MD, executive director of the Basser Center for BRCA, are interviewed on the new Basser Cancer Interception Institute’s efforts studying a vaccine to reduce cancer risk among individuals who carry BRCA1/2 mutations by recognizing and killing cancer cells “before anyone even knew they were there.” Mindy and Jon Gray gift $55M to Penn’s Basser Center for BRCA for Cancer Interception Institute The Cancer Letter News | September 2022 Penn alumni Mindy and Jon Gray have gifted $55 million to the University of Pennsylvania’s Basser Center at the Abramson Cancer Center to establish the Basser Cancer Interception Institute, which aims to target the early stages of hereditary cancers. Integrating Genetic Testing in Electronic Health Records Saves Time, Penn Study Finds Penn Medicine News News | September 2022 Ordering and managing genomic testing in electronic health records significantly cut the time Penn Medicine clinicians spent doing it. University Of Pennsylvania Receives $55 Million Gift To Study, Treat Hereditary Cancers Forbes News | September 2022 The University of Pennsylvania has received a $55 million gift for the study and treatment of hereditary cancers. The gift, from Penn alumni Mindy and Jon Gray, will be used to establish the Basser Cancer Interception Institute, at the Basser Center. $55 Million Gift Creates New “Cancer Interception” Institute at Penn’s Basser Center for BRCA to Stop Hereditary Cancers at the Earliest Stages Penn Medicine News News | September 2022 Funding for the Institute from Mindy and Jon Gray will propel early detection and prevention of breast, ovarian, pancreatic, and prostate cancers. $55 Million Gift to Penn is Aimed at Stopping Breast Cancer Before It Starts The Philadelphia Inquirer News | September 2022 Mindy Gray and her husband, Blackstone president Jon Gray, gave the money in honor of Mindy's sister Faith Basser. Blackstone’s Gray Gives UPenn $55 Million for Cancer Prevention Bloomberg News | September 2022 Jon and Mindy Gray’s gift will fund an institute focused on early detection of breast, ovarian, pancreatic and prostate cancers. Pagination First page« First Previous page‹‹ … Page3 Page4 Page5 Page6 Current page7 Page8 Page9 Page10 Page11 … Next page›› Last pageLast »
Volunteering for Cancer Research: An Act of Love Penn Medicine News News Motivated by generations past, present, and future, two patients participating in the first-of-its-kind clinical trial are testing an experimental approach to stop cancer in its tracks at the earliest stages of development at the Basser Center.
Basser Jean Bash Brings Out Celebrities for a Good Cause Bloomberg News | November 2022 Grammy Award-winning artist, songwriter, and actress Sara Bareilles performed at the Basser Center's fourth Basser Jean Bash last week in New York City. The sold-out event raised nearly $17 million to help find a cure for BRCA-related cancers.
See What Your Favorite Stars Are Up To: Sara Bareilles People News | November 2022 Sara Bareilles shows off her smile while attending the 4th Annual Basser Jean Bash held at The Glasshouse in N.Y.C. on Nov. 15, 2022.
Basser Center Holds Fundraiser in Manhattan to Help Cure Cancer abc7NY News | November 2022 The Basser Center held its Basser Jean Bash on November 15th in Manhattan where all attendees wore their most stylish denim. The event it was an event about your "genes" that helped to raise money to find a cure for BRCA-related cancers.
Basser Center Holds Fundraiser In NYC To Help Cure Cancer MSN.com News | November 2022 The Basser Center's celebrated their 10th year anniversary with a fundraiser that helps to raise money to find a cure for BRCA-related cancers.
Analysis of Matched Primary and Recurrent BRCA1/2 Mutation-Associated Tumors Identifies Recurrence-Specific Drivers Nature Communications News | November 2022 The Basser Center research team worked to address outstanding questions about cancer recurrence in BRCA1/2 mutation carriers by performing an analysis of paired primary and recurrent BRCA1/2 mutation-associated tumors.
Penn Study Illuminates Why Cancers Caused by BRCA Mutations Recur Penn Medicine News News | November 2022 Our research team at the Basser Center for BRCA uncovers possible drivers of recurrent breast and ovarian cancers among women carrying high-risk genetic mutations, pointing to methods to more effectively treat disease.
Research Groups Across the US Testing Vaccines to Help Prevent, Terminate Cancer ABC10 News San Diego News | October 2022 Basser executive director, Susan Domchek, MD, speaks on a vaccine that could prevent breast cancer from developing in certain patients. She says, “We’re in the midst of a trial where we’re first vaccinating BRCA1 and BRCA2 mutation carriers who have had cancer of any type. Then we will start vaccinating BRCA1 and BRCA2 mutation carriers who have never had any cancers.”
For Patients with Earliest Stage of Breast Cancer, How Much Treatment is Enough? USA Today News | October 2022 Doctors are now trying to “right-size” care for patients with ductal carcinoma in situ, what’s sometimes called “stage zero” breast cancer. Susan Domchek, MD, was quoted on these treatment opportunities and risks for patients.
What’s the BRCA Gene, and How Does It Affect Breast Cancer? Katie Couric Media News | October 2022 Susan Domchek, MD discusses the significance of genetics, genetic testing, the risk of developing cancer with a BRCA gene mutation and more.
Groundbreaking Study to Test a Breast Cancer Vaccine Fox29 News | October 2022 Dr. Susan Domchek, executive director of the Basser Center, is interviewed with her patient, Karen, on what leading a vaccine trial to prevent breast cancer can really mean for patients and their families.
After Giving Up on Cancer Vaccines, Doctors Start to Find Hope The New York Times News | October 2022 Susan Domchek, MD, Basser Center executive director, discusses emerging efforts to create cancer vaccines for diseases including those delivered after patients have blood tests to find cancer cells before they show up in scans or standard tests.
The Race to Make a Vaccine for Breast Cancer TIME News | October 2022 Robert Vonderheide, MD, PhD, director of the Abramson Cancer Center, and Susan Domchek, MD, executive director of the Basser Center for BRCA, are interviewed on the new Basser Cancer Interception Institute’s efforts studying a vaccine to reduce cancer risk among individuals who carry BRCA1/2 mutations by recognizing and killing cancer cells “before anyone even knew they were there.”
Mindy and Jon Gray gift $55M to Penn’s Basser Center for BRCA for Cancer Interception Institute The Cancer Letter News | September 2022 Penn alumni Mindy and Jon Gray have gifted $55 million to the University of Pennsylvania’s Basser Center at the Abramson Cancer Center to establish the Basser Cancer Interception Institute, which aims to target the early stages of hereditary cancers.
Integrating Genetic Testing in Electronic Health Records Saves Time, Penn Study Finds Penn Medicine News News | September 2022 Ordering and managing genomic testing in electronic health records significantly cut the time Penn Medicine clinicians spent doing it.
University Of Pennsylvania Receives $55 Million Gift To Study, Treat Hereditary Cancers Forbes News | September 2022 The University of Pennsylvania has received a $55 million gift for the study and treatment of hereditary cancers. The gift, from Penn alumni Mindy and Jon Gray, will be used to establish the Basser Cancer Interception Institute, at the Basser Center.
$55 Million Gift Creates New “Cancer Interception” Institute at Penn’s Basser Center for BRCA to Stop Hereditary Cancers at the Earliest Stages Penn Medicine News News | September 2022 Funding for the Institute from Mindy and Jon Gray will propel early detection and prevention of breast, ovarian, pancreatic, and prostate cancers.
$55 Million Gift to Penn is Aimed at Stopping Breast Cancer Before It Starts The Philadelphia Inquirer News | September 2022 Mindy Gray and her husband, Blackstone president Jon Gray, gave the money in honor of Mindy's sister Faith Basser.
Blackstone’s Gray Gives UPenn $55 Million for Cancer Prevention Bloomberg News | September 2022 Jon and Mindy Gray’s gift will fund an institute focused on early detection of breast, ovarian, pancreatic and prostate cancers.
